2. Inhibitory Antibodies
  3. Biosimilar Antibodies
  4. Monoclonal Antibodies

Monoclonal Antibodies

Monoclonal antibodies (mAbs) are highly homogeneous antibodies produced by a single B-cell clone that are directed only against a specific antigenic epitope and specifically bind to unique epitopes on targets such as pathogens and cancer cells. Monoclonal antibody drugs have been widely marketed and applied in clinics worldwide, helping countless patients to improve their survival rate and quality of life.

Monoclonal Antibodies (2450):

Cat. No. Product Name Purity Image
  • HY-P9907
    Trastuzumab 99.80%  
    Trastuzumab is a humanized IgG1 monoclonal antibody that selectively binds to HER2 with high affinity. Trastuzumab can be used for the research of HER2-positive metastatic breast cancer and gastric cancer. (Note: The product specifications below only indicate the effective content of Trastuzumab. The component ratio of this product is Trastuzumab : excipients = 1:0.6-1:0.9.)
    (13)
  • HY-P9905
    Cetuximab 99.81%  
    Cetuximab (C225) is a human IgG1 monoclonal antibody that inhibits epidermal growth factor receptor (EGFR), with a Kd of 0.201 nM for EGFR by SPR. Cetuximab has potent antitumor activity.
    (9)
  • HY-P9906
    Bevacizumab ≥99.0%  
    Bevacizumab, a humanized IgG1 monoclonal antibody, specifically binds to all VEGF-A isoforms with high affinity.
    (12)
  • HY-P9902
    Pembrolizumab 99.74%  
    Pembrolizumab (MK-3475) is a humanized IgG4 antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy.
    (9)
  • HY-P9904
    Atezolizumab 99.9%  
    Atezolizumab (MPDL3280A) is a selective humanized monoclonal IgG1 antibody against programmed death ligand 1 (PD-L1), used for cancer research.
    (9)
  • HY-P9S0062
    Rosnilimab (Mouse IgG2a) 98.0%  
    Rosnilimab (Mouse IgG2a) is a mouse-derived IgG2a, Rosnilimab. Rosnilimab is a PD-1 agonistic monoclonal antibody. Rosnilimab (Mouse IgG2a) can be used in research related to ulcerative colitis.
    (1)
  • HY-P992159
    Anti-ZnT8 Antibody (mAb43)  
    Anti-ZnT8 Antibody (mAb43) is a monoclonal antibody targeting the zinc transporter ZnT8, with islet-specific biodistribution characteristics. Anti-ZnT8 Antibody (mAb43) binds to extracellular ZnT8 on the surface of pancreatic β-cells and masks its insulin-co-localizing sites to block autoimmune recognition. Anti-ZnT8 Antibody (mAb43) also promotes an increase in the proportion of regulatory T cells and inhibits B cell antigen presentation, thereby effectively blocking the T cell-mediated cascade of β-cell destruction. Anti-ZnT8 Antibody (mAb43) eliminates insulitis, preserves β-cell mass and induces seroconversion of autoantibodies, without directly altering the insulin secretion function or content of β-cells. Anti-ZnT8 Antibody (mAb43) can be used for research related to type 1 diabetes.
    Anti-ZnT8 Antibody (mAb43)
  • HY-P99528
    Vandortuzumab vedotin 99.52%  
    Vandortuzumab vedotin (DSTP 3086S; RG 7450) is a STEAP1-targeted antibody-drug conjugate (ADC). Vandortuzumab vedotin binds specifically to STEAP1, triggers internalization of the conjugate complex, mediates intracellular release of monomethyl auristatin E, inhibits cell division, and induces cell death. Vandortuzumab vedotin exhibits antitumor activity in preclinical prostate cancer xenografts. Vandortuzumab vedotin can be used for the research of metastatic castration-resistant prostate cancer.
    (1)
  • HY-P9926
    Dupilumab ≥99.2%  
    Dupilumab (REGN-668) is a fully human mAb to IL-4 receptor α (IL-4Rα) that inhibits both IL-4 and IL-13 signaling, markedly improved moderate-to-severe atopic dermatitis.
    (7)
  • HY-P9908
    Adalimumab 99.62%  
    Adalimumab is a human monoclonal IgG1 antibody targeting tumour necrosis factor α (TNF-α).
    (9)
  • HY-P99045
    Sacituzumab 99.9%  
    Sacituzumab is a humanized IgG1 monoclonal antibody targeting Trophoblast cell surface antigen 2 (TROP2). Sacituzumab demonstrates a lack of antitumor effects alone and does not inhibit the function of TROP-2 during tumor metastasis, binding to the linear epitopes of TROP-2 protein. Sacituzumab can be used for the synthesis of antibody-drug conjugates (ADC) drug Sacituzumab govitecan (HY-132254). Sacituzumab govitecan can be used in the field of triple-negative breast cancer.
    (4)
  • HY-P99355
    Bimagrumab 99.31%  
    Bimagrumab (Anti-ACVR2B Reference Antibody) is a human monoclonal antibody that blocks activin type II receptor (ActRII), with KDs of 1.7 pM and 434 pM for human ActRIIB and ActRIIA, respectively. Bimagrumab can be used for the research of pathological muscle loss and weakness.
    (8)
  • HY-P9913
    Rituximab 99.85%  
    Rituximab is an anti-CD20 chimeric monoclonal antibody used for research of certain autoimmune diseases and cancer.
    (7)
  • HY-P9903
    Nivolumab 99.63%  
    Nivolumab is a programmed death receptor-1 (PD-1) blocking human IgG4 antibody to treat advanced (metastatic) non-small cell lung cancer.
    (8)
  • HY-P9917
    Tocilizumab 99.67%  
    Tocilizumab (Anti-Human IL6R, Humanized Antibody) is an anti-human interleukin-6 receptor (IL-6R) neutralizing antibody, prevents binding of IL-6 to the IL-6R, thereby inhibiting both classic and trans-signaling. Tocilizumab (Anti-Human IL6R, Humanized Antibody) can be used for the treatment of rheumatoid arthritis. Tocilizumab is remarkablely effective for the study of severe COVID-19 (coronavirus disease).
    (8)
  • HY-P9970
    Infliximab  
    Infliximab (Avakine) is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α. Infliximab prevents the interaction of TNF-α with TNF-α receptor (TNFR1 and TNFR2). Infliximab has the potential for autoimmune, chronic inflammatory diseases and diabetic neuropathy research.
    The component ratio of this product is Active ingredient : Excipients = 9 : 47.
    (11)
  • HY-P990007
    Tulisokibart 99.00%  
    Tulisokibart (PRA023) is a humanized IgG1-κ monoclonal antibody. Tulisokibart targets to TNFSF15/TL1A. Tulisokibart can be used to study a variety of inflammatory/fibrotic diseases, such as Crohn's Disease (CD) and ulcerative colitis.
    (4)
  • HY-P990110
    Lecanemab (Mouse IGG2a) 99.88%  
    Lecanemab (Mouse IGG2a) (Mab158) is a monoclonal antibody that targets soluble β-amyloid and has the potential to reduce cognitive decline. The variable region of Lecanemab (Mouse IGG2a) is consistent with that of Lecanemab, while the constant region is of Mouse IGG2a sequence. Lecanemab (Mouse IGG2a) almost abolishes Aβ accumulation in astrocytes and rescues neurons from Aβ-induced cell death. Lecanemab (Mouse IGG2a) holds promise for research in the field of Alzheimer's disease.
    (3)
  • HY-P99366A
    Tezepelumab (anti-TSLP) ≥99.0%  
    Tezepelumab (anti-TSLP) is human monoclonal antibody (IgG2λ) that binds specifically to TSLP, blocking it from interacting with its heterodimeric receptor. Tezepelumab can be used for the research of severe, uncontrolled asthma.
    (2)
  • HY-P9915
    Daratumumab 99.10%  
    Daratumumab (Anti-Human CD38) is the first-in-class human-specific anti-CD38 monoclonal antibody (IgG1). Daratumumab has anti-multiple myeloma (MM) effect. Daratumumab impairs MM cell adhesion, which results in an increased sensitivity of MM to proteasome inhibition.
    (9)